Edition:
United Kingdom

Array BioPharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

47.85USD
29 Jul 2019
Change (% chg)

$0.56 (+1.18%)
Prev Close
$47.29
Open
$47.96
Day's High
$47.97
Day's Low
$47.85
Volume
8,137,302
Avg. Vol
1,262,824
52-wk High
$47.97
52-wk Low
$12.58

Latest Key Developments (Source: Significant Developments)

Array Biopharma Announces Presentation Of Updated OS From Phase 3 Columbus Trial Of Braftovi + Mektovi
Wednesday, 29 May 2019 

May 29 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA ANNOUNCES PRESENTATION OF UPDATED OVERALL SURVIVAL FROM THE PHASE 3 COLUMBUS TRIAL OF BRAFTOVI + MEKTOVI IN ADVANCED BRAF-MUTANT MELANOMA AT 2019 ASCO ANNUAL MEETING.ANALYSIS ESTIMATES 47% AND 39% OF PATIENTS ALIVE AT 3 AND 4 YEARS, RESPECTIVELY.CONSISTENT WITH PRIOR READOUTS, BRAFTOVI+MEKTOVI DEMONSTRATES 33.6 MONTHS MEDIAN OVERALL SURVIVAL WITH LONGER MEDIAN FOLLOW UP OVER 48 MONTHS.  Full Article

Array Biopharma May Offer And Sell Shares Of Common Stock Having An Offering Price Of Up To $150 Mln Through Jefferies
Tuesday, 7 May 2019 

May 7 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA INC - MAY OFFER AND SELL SHARES OF COMMON STOCK HAVING AN OFFERING PRICE OF UP TO $150 MILLION THROUGH JEFFERIES - SEC FILING.  Full Article

Array Biopharma Reports Q3 Loss Per Share Of $0.17
Tuesday, 7 May 2019 

May 7 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER OF FISCAL 2019.Q3 LOSS PER SHARE $0.17.Q3 REVENUE $64.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $54 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $-0.20 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2019 WERE $479 MILLION.NET PRODUCT SALES FOR BRAFTOVI + MEKTOVI FOR Q3 OF FISCAL 2019 WERE $35.1 MILLION VERSUS $22.7 MILLION FOR Q2 OF FISCAL 2019.BEACON CRC PHASE 3 TRIAL INTERIM ANALYSIS REMAINS ON TRACK TO REPORT OUT THIS QUARTER.  Full Article

Array Biopharma Q2 Loss Per Share $0.05
Tuesday, 5 Feb 2019 

Feb 5 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF FISCAL 2019.Q2 LOSS PER SHARE $0.05.Q2 REVENUE $82.5 MILLION.Q2 REVENUE ESTIMATE $52.4 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $-0.15 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF DECEMBER 31, 2018 WERE $478 MILLION.ARRAY - AFTER CONSULTATION WITH FDA, EMA, INITIATED AN AMENDMENT TO BEACON CRC PROTOCOL TO ALLOW FOR AN INTERIM ANALYSIS OF TRIAL ENDPOINTS.SHOULD AN ANALYSIS FROM STUDY BE SUPPORTIVE, CO PLANS TO USE IT TO SEEK ACCELERATED APPROVAL IN U.S..COMPANY ANTICIPATES TOPLINE RESULTS FROM ANALYSIS OF TRIAL ENDPOINTS IN FIRST HALF OF 2019.BEACON CRC TRIAL HAS COMPLETED ENROLLMENT..  Full Article

Array Biopharma reports Q1 results
Tuesday, 30 Oct 2018 

Oct 30 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF FISCAL 2019.Q1 LOSS PER SHARE $0.12.Q1 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF SEPTEMBER 30, 2018 WERE $415 MILLION.EUROPEAN COMMISSION APPROVES BRAFTOVI + MEKTOVI FOR ADVANCED BRAF-MUTANT MELANOMA.ARRAY BIOPHARMA - BEACON CRC TRIAL CONTINUES TO ENROLL, CO EXPECTS TO COMPLETE ENROLLMENT OF TRIAL AROUND END OF 2018.QTRLY TOTAL REVENUE $56.9 MILLION VERSUS $29.8 MILLION.Q1 REVENUE VIEW $34.5 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

U.S. FDA Approves Array Biopharma's NDA For Mektovi
Wednesday, 27 Jun 2018 

June 27 (Reuters) - U.S. Food and Drug Administration::U.S. FDA APPROVES ARRAY BIOPHARMA'S NDA FOR MEKTOVI.U.S. FDA SAYS RECOMMENDED DOSE FOR ARRAY'S MEKTOVI IS 45 MG ORALLY TWICE DAILY IN COMBINATION WITH ENCORAFENIB.U.S. FDA SAYS MEKTOVI IS INDICATED, IN COMBINATION WITH ENCORAFENIB, FOR TREATING PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF MUTATION.  Full Article

Array Biopharma Announces Additional Median Overall Survival Results Of Encorafenib And Binimetinib
Monday, 4 Jun 2018 

June 4 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA ANNOUNCES ADDITIONAL MEDIAN OVERALL SURVIVAL RESULTS OF ENCORAFENIB AND BINIMETINIB IN PATIENTS WITH BRAF-MUTANT ADVANCED MELANOMA.ARRAY BIOPHARMA INC - COMBINATION OF ENCORAFENIB AND BINIMETINIB ACHIEVED 33.6 MONTH MEDIAN OVERALL SURVIVAL.  Full Article

Array Biopharma Says Entered Into Controlled Equity Offerings Sales Agreement With Cantor Fitzgerald
Wednesday, 9 May 2018 

May 9 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA INC SAYS ENTERED INTO CONTROLLED EQUITY OFFERINGSM SALES AGREEMENT WITH CANTOR FITZGERALD & CO - SEC FILING.ARRAY BIOPHARMA INC SAYS MAY OFFER AND SELL UP TO $125.0 MILLION OF COMMON STOCK OF THROUGH CANTOR FITZGERALD & CO.  Full Article

Array Biopharma Q2 Loss Per Share $0.17
Tuesday, 6 Feb 2018 

Feb 6 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF FISCAL 2018.Q2 LOSS PER SHARE $0.17.Q2 REVENUE $42.2 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.23, REVENUE VIEW $26.7 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Array Biopharma Contributes Rights And Assets Related To Arry-797 Drug Program To Yarra Therapeutics
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA SAYS ON DEC 21, CO CONTRIBUTED CERTAIN RIGHTS AND ASSETS RELATED TO ARRY-797 DRUG PROGRAM TO YARRA THERAPEUTICS - SEC FILING.ARRAY BIOPHARMA SAYS FORMED YARRA TO FURTHER DEVELOP, COMMERCIALIZE THERAPEUTICS TARGETED TOWARDS RARE DISEASES, INCLUDING ARRY-797 DRUG PROGRAM.ARRAY BIOPHARMA - YARRA WILL BE LED BY BRYAN STUART, WHO WILL SERVE AS YARRA'S PRESIDENT AND CHIEF EXECUTIVE OFFICER.  Full Article

RPT-BUZZ-U.S. stocks weekly: Asset grab

(Repeats from Friday. Updates chart) ** S&P 500 extends win streak to three weeks, adds 2.2%. Rate-cut euphoria and trade optimism spur index to record highs. Bonds and commodities also catch bids ** Indeed, studies suggested sudden quiet could end with a bang ** And as the SPX went for a second round with resistance , the Dow caught a second wind ** Now the Dow is trying to make the big leap as the SPX notched a "defensive" new high ** Every sector rises: Energy and tech s